Congrats on the IND clearance of ABA-101! We look forward to watching your continued progress towards making a difference for patients living with Progressive Multiple Sclerosis.
We’re excited to announce IND clearance of ABA-101 for Progressive Multiple Sclerosis (MS). It’s the first open IND for our best-in-class autologous TCR-Treg cell therapy platform. We expect to initiate our Phase 1 study later this year. This is an important milestone for us and for patients. ABA-101 was specifically designed to benefit Progressive MS patients who have no or insufficient treatment options today. bit.ly/3LiotOa
Biotech Commercialization Leadership
1moCongrats Abata leadership team ABA-101 has amazing potential...